<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511299</url>
  </required_header>
  <id_info>
    <org_study_id>1983/105/II/2020</org_study_id>
    <nct_id>NCT04511299</nct_id>
  </id_info>
  <brief_title>Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery</brief_title>
  <official_title>Impact of Fish Oil-enriched Intravenous Lipid Emulsion in Parenteral Nutrition of Phospholipid Fatty Acid Composition and Inflammatory Response in Infants After Gastrointestinal Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Soetomo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Soetomo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to compare the impact of fish oil-enriched intravenous lipid emulsion to&#xD;
      standard Intravenous lipid emulsion on fatty acid composition and inflammatory response&#xD;
      (IL-1β and IL-8 levels) in infants after gastrointestinal surgery. Our hypothesis is the fish&#xD;
      oil-enriched intravenous lipid emulsion can improve the fatty acid composition and lower the&#xD;
      inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted in infants post gastrointestinal surgery that requires parenteral&#xD;
      nutrition for at least 3 days. Subjects are classified into two groups. Group 1 received&#xD;
      standard IVFE and group 2 received ω-3-enriched IVFE. The type of intravenous standard and&#xD;
      omega-3-enriched fat emulsion used in this study are Lipofundin 20% and SMOFlipid 20%,&#xD;
      respectively, both administered for three consecutive days after surgery (72 hours) in 1-4&#xD;
      gram/kilogram/day dosing. The inflammatory response (IL-1β and IL-8 levels) and fatty acid&#xD;
      composition are checked from blood plasma. Blood examination is done before the surgery and 3&#xD;
      days after the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Actual">July 13, 2020</completion_date>
  <primary_completion_date type="Actual">July 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatty Acids Composition</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>The percentage of fatty acid consentration from total fatty acids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>Interleukin 1b and Interleukin 8 levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>Hemoglobin value in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>Leukocyte value in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive Protein</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>C Reactive Protein valuel in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>3 days (before surgery and after surgery)</time_frame>
    <description>Albumin value in all subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Fish oil-enriched intravenous lipid emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard intavenous lipid emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMOFlipid 20%</intervention_name>
    <description>Fish oil-enriched intravenous lipid emulsion</description>
    <arm_group_label>Fish oil-enriched intravenous lipid emulsion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lipofundin 20%</intervention_name>
    <description>MCT/LCT standard intravenous lipid emulsion</description>
    <arm_group_label>Standard intavenous lipid emulsion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  willing to participate in this study (through informed consent)&#xD;
&#xD;
          -  undergo gastrointestinal surgery&#xD;
&#xD;
          -  get parenteral nutrition for at least 3 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic diseases&#xD;
&#xD;
          -  allergic to fish, egg, soy and/or nut proteins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meta H Hanindita</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Soetomo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Soetomo General Hospital</name>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Soetomo General Hospital</investigator_affiliation>
    <investigator_full_name>Meta Herdiana Hanindita, dr., Sp.A (K)</investigator_full_name>
    <investigator_title>MD, Pediatrician (Consultant)</investigator_title>
  </responsible_party>
  <keyword>Parenteral nutrition</keyword>
  <keyword>Interleukin-1b</keyword>
  <keyword>Interleukin-8</keyword>
  <keyword>Lipid emulsion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

